Pharmnovo is a “virtual” R&D biopharma company performing research and development in collaboration with internationally leading academic and pharmaceutical scientists in their fields related to pain and pain therapy.
THE PRE-CLINICAL PHASE of the PN6047 development project is fundamentally complete and planning is now in train for regulatory toxicology testing and first in man clinical trials. The regulatory toxicology programme is being designed in collaboration with selected experts who will advise and manage the conduct and analysis of the animal testing.
Clinical input into the remaining phases of the project is clearly necessary and PharmNovo has put together a first class clinical team. The team includes; Andrew Rice, Professor of Pain Research, Imperial College, London; link), Dr Roger Knaggs, Associate Professor in Pharmacy Practice, University of Nottingham (link), Chair of the UK Clinical Pharmacy Association pain management group) and Dr Peder Andersson, Chief Executive Officer, Biosergen.
Together with Board member Dr Anthony Ford, the team has huge experience of overseeing clinical testing of new drugs, interaction with regulatory bodies and progression to the market.